IMPLANTABLE NANOPUMPS FOR BIOMEDICINE

Information

  • Research Project
  • 2518992
  • ApplicationId
    2518992
  • Core Project Number
    R44GM048894
  • Full Project Number
    5R44GM048894-03
  • Serial Number
    48894
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/1993 - 31 years ago
  • Project End Date
    7/31/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    9/1/1997 - 27 years ago
  • Budget End Date
    7/31/2000 - 24 years ago
  • Fiscal Year
    1997
  • Support Year
    3
  • Suffix
  • Award Notice Date
    8/20/1997 - 27 years ago

IMPLANTABLE NANOPUMPS FOR BIOMEDICINE

We will build miniature. solid-state pumps for medicine. These pumps are intended for eventual use as indwelling prostheses in patients needing long-term. controlled delivery of drug into a specific organ or tissue. Our pumps are piezoelectric de vices, just over one mm in diameter. They give precise, programmed delivery of very small, I-2pl drug volumes. They can therefore be used as indwelling chemical stimulators for delivering drugs to small targets like brain nuclei or blood vessels. One important use now emerging would be delivery of neurotrophic growth factors directly into ailing or damaged brain nuclei. We showed in Phase I that piezoelectric pumps work well with biomedically-relevant fluids; we built and characterized two types of piezoelectric pumps for biomedicine. In Phase II we will design and build pro to types of implantable systems that include pump, drug reservoir, fluid delivery microchannels, and drug dialysis tips. To capitalize on the benefits of small size and precision pumping we will design our prototype for use as an intracranial "neuroprosthetic" drug pump, suitable for dopamine replacement therapy (and/or growth factor therapy) in Parkinson's disease. In Phase III we will provide pumping systems to selected members of the neuroscience community for beta-site evaluation in animal. PROPOSED COMMERCIAL APPLICATION: The technology we are developing can lead to a whole new class of chemical-stimulation prosthetic devices in medicine. In the neuroprosthetic market alone there are about 500,000 patients with Parkinson's, and hundreds of thousands more with other diseases amenable to our chemical microstimulation treatment, such as epilepsy chronic pain, Alzheimer's, and cancer

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R44
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    MICROFAB TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    PLANO
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    75074
  • Organization District
    UNITED STATES